Clinical Trial Update: Efficacy of Lactobacillus Paracasei PS23 for Patients With Post-COVID-19 Syndrome [NA]

View source ↗

Summary

A clinical trial evaluating Lactobacillus paracasei PS23 for post-COVID-19 syndrome has been terminated, with no efficacy results reported in the record.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Lactobacillus paracasei PS23 (Lactobacillus paracasei PS23)

Snippet

Sponsor: Mackay Memorial Hospital | Conditions: Post-COVID-19 Syndrome | NA | Status: TERMINATED